Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Immunotherapies targeting immune checkpoints are fast-developing therapeutic approaches adopted for several tumor types that trigger unprecedented rates of durable clinical responses. Immune checkpoint programmed cell death protein 1 (PD-1), expressed primarily by T cells, and programmed cell death...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/10/1554 |
| _version_ | 1797710518543187968 |
|---|---|
| author | Zuzana Macek Jilkova Caroline Aspord Thomas Decaens |
| author_facet | Zuzana Macek Jilkova Caroline Aspord Thomas Decaens |
| author_sort | Zuzana Macek Jilkova |
| collection | DOAJ |
| description | Immunotherapies targeting immune checkpoints are fast-developing therapeutic approaches adopted for several tumor types that trigger unprecedented rates of durable clinical responses. Immune checkpoint programmed cell death protein 1 (PD-1), expressed primarily by T cells, and programmed cell death ligand 1 (PD-L1), expressed mainly by tumor cells, macrophages, and dendritic cells, are molecules that impede immune function, thereby allowing tumor cells to proliferate, grow and spread. PD-1/PD-L1 checkpoint inhibitors have emerged as a promising treatment strategy of hepatocellular carcinoma (HCC). However, only a minority of HCC patients benefit from this therapy. To find a niche for immune checkpoint inhibition in HCC patients, future strategies might require predictive factor-based patient selection, to identify patients who are likely to respond to the said therapy and combination strategies in order to enhance anti-tumor efficacy and clinical success. This review provides an overview of the most recent data pertaining to predictive factors for response to PD-1/PD-L1 checkpoint inhibition in the field of HCC. |
| first_indexed | 2024-03-12T06:53:18Z |
| format | Article |
| id | doaj.art-9659c14fac2248dc8f525aa3942552e8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:53:18Z |
| publishDate | 2019-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9659c14fac2248dc8f525aa3942552e82023-09-03T00:10:35ZengMDPI AGCancers2072-66942019-10-011110155410.3390/cancers11101554cancers11101554Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and ChallengesZuzana Macek Jilkova0Caroline Aspord1Thomas Decaens2Université Grenoble Alpes, 38000 Grenoble, FranceUniversité Grenoble Alpes, 38000 Grenoble, FranceUniversité Grenoble Alpes, 38000 Grenoble, FranceImmunotherapies targeting immune checkpoints are fast-developing therapeutic approaches adopted for several tumor types that trigger unprecedented rates of durable clinical responses. Immune checkpoint programmed cell death protein 1 (PD-1), expressed primarily by T cells, and programmed cell death ligand 1 (PD-L1), expressed mainly by tumor cells, macrophages, and dendritic cells, are molecules that impede immune function, thereby allowing tumor cells to proliferate, grow and spread. PD-1/PD-L1 checkpoint inhibitors have emerged as a promising treatment strategy of hepatocellular carcinoma (HCC). However, only a minority of HCC patients benefit from this therapy. To find a niche for immune checkpoint inhibition in HCC patients, future strategies might require predictive factor-based patient selection, to identify patients who are likely to respond to the said therapy and combination strategies in order to enhance anti-tumor efficacy and clinical success. This review provides an overview of the most recent data pertaining to predictive factors for response to PD-1/PD-L1 checkpoint inhibition in the field of HCC.https://www.mdpi.com/2072-6694/11/10/1554pd-1pd-l1hepatocellular carcinomapredictive factorsimmunotherapyimmune checkpoint inhibition |
| spellingShingle | Zuzana Macek Jilkova Caroline Aspord Thomas Decaens Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges Cancers pd-1 pd-l1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition |
| title | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges |
| title_full | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges |
| title_fullStr | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges |
| title_full_unstemmed | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges |
| title_short | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges |
| title_sort | predictive factors for response to pd 1 pd l1 checkpoint inhibition in the field of hepatocellular carcinoma current status and challenges |
| topic | pd-1 pd-l1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition |
| url | https://www.mdpi.com/2072-6694/11/10/1554 |
| work_keys_str_mv | AT zuzanamacekjilkova predictivefactorsforresponsetopd1pdl1checkpointinhibitioninthefieldofhepatocellularcarcinomacurrentstatusandchallenges AT carolineaspord predictivefactorsforresponsetopd1pdl1checkpointinhibitioninthefieldofhepatocellularcarcinomacurrentstatusandchallenges AT thomasdecaens predictivefactorsforresponsetopd1pdl1checkpointinhibitioninthefieldofhepatocellularcarcinomacurrentstatusandchallenges |